Compare Agilent Technologies Inc (A) vs Applovin Corporation (APP) Price & Performance

Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.

The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.

AppLovin (APP) trades at $346.80, down 3.32% amid a bearish technical outlook despite strong fundamentals. The stock faces selling pressure after Q2 revenue missed expectations, though it maintains exceptional profitability with 64.58% net margins and 53% YoY revenue growth. Analyst consensus remains bullish with an $569.60 price target, but technical indicators show 18 sell signals versus 2 buys.

The stock presents a growth-at-a-reasonable-price opportunity post-selloff, trading at 26x P/E with 80% analyst buy ratings. Key risks include execution volatility in AI-driven ad pricing and high valuation multiples. Upside depends on Q3 results meeting elevated guidance of 47% growth.